Compare · BEN vs HQL
BEN vs HQL
Side-by-side comparison of Franklin Resources Inc. (BEN) and abrdn Life Sciences Investors Shares of Beneficial Interest (HQL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BEN and HQL operate in Investment Managers (Finance), so they compete in similar markets.
- BEN is the larger of the two at $17.60B, about 33.3x HQL ($528.0M).
- Over the past year, BEN is up 41.1% and HQL is up 44.5% - HQL leads by 3.5 points.
- BEN has been more active in the news (13 items in the past 4 weeks vs 1 for HQL).
- BEN has more recent analyst coverage (24 ratings vs 0 for HQL).
- Company
- Franklin Resources Inc.
- abrdn Life Sciences Investors Shares of Beneficial Interest
- Price
- $34.65-0.26%
- $20.55-0.29%
- Market cap
- $17.60B
- $528.0M
- 1M return
- +2.70%
- -0.15%
- 1Y return
- +41.05%
- +44.51%
- Industry
- Investment Managers
- Investment Managers
- Exchange
- NYSE
- NYSE
- IPO
- 1992
- News (4w)
- 13
- 1
- Recent ratings
- 24
- 0
Franklin Resources Inc.
Franklin Resources, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to individuals, institutions, pension plans, trusts, and partnerships. It launches equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. The firm invests in the public equity, fixed income, and alternative markets. Franklin Resources, Inc. was founded in 1947 and is based in San Mateo, California with an additional office in Hyderabad, India.
abrdn Life Sciences Investors Shares of Beneficial Interest
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Latest BEN
- Leading European Real Assets Manager Stoneshield Capital to Join Forces with Franklin Templeton and Clarion Partners
- Leading European Real Assets Manager Stoneshield Capital to Join Forces with Franklin Templeton and Clarion Partners
- Franklin Templeton, Inc. Announces Preliminary Month-End Assets Under Management
- Chief Executive Officer Johnson Jennifer M covered exercise/tax liability with 116,053 shares, decreasing direct ownership by 3% to 3,437,981 units (SEC Form 4)
- Executive Chairman Johnson Gregory E covered exercise/tax liability with 10,568 shares, decreasing direct ownership by 0.39% to 2,676,986 units (SEC Form 4)
- Chief Accounting Officer Oshita Lindsey Harumi covered exercise/tax liability with 2,598 shares, decreasing direct ownership by 9% to 26,129 units (SEC Form 4)
- Co-President, CFO & COO Nicholls Matthew covered exercise/tax liability with 61,533 shares, decreasing direct ownership by 8% to 717,264 units (SEC Form 4)
- Co-President, Public Markets Murphy Terrence covered exercise/tax liability with 25,125 shares, decreasing direct ownership by 6% to 390,884 units (SEC Form 4)
- EVP, General Counsel Merchant Thomas C covered exercise/tax liability with 9,807 shares, decreasing direct ownership by 11% to 82,805 units (SEC Form 4)
- Co-President, Chief Commercial Gamba Daniel covered exercise/tax liability with 64,136 shares, decreasing direct ownership by 10% to 608,584 units (SEC Form 4)
Latest HQL
- SEC Form N-PX filed by abrdn Life Sciences Investors Shares of Beneficial Interest
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- Director Mahai Chris Lavictoire bought $10,498 worth of shares (527 units at $19.92) (SEC Form 4)
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- SEC Form 3 filed by new insider Mahai Chris Lavictoire
- SEC Form N-CSRS filed by abrdn Life Sciences Investors Shares of Beneficial Interest
- ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts